TransCode Therapeutics Inc Dossier
Qualitative Analysis
Business overview
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a clinical-stage oncology company dedicated to defeating cancer through the intelligent design and targeted delivery of RNA therapeutics and immuno-oncology treatments. The company's core foundation is its proprietary TTX (TransCode Therapeutics) nanoparticle delivery platform, which utilizes an iron-oxide nanoparticle conjugated with specific RNA payloads. Unlike traditional lipid nanoparticles (LNPs) that primarily accumulate in the liver, the TTX platform is engineered to bypass renal clearance and achieve high penetration into tumor tissues and metastatic sites across the body. TransCode's lead therapeutic candidate, TTX-MC138, is a first-in-class antagomiR designed to inhibit microRNA-10b (miR-10b), a well-documented biomarker and driver of tumor metastasis. The company is also advancing a broader pipeline of preclinical assets, including TTX-siPDL1, TTX-RIGA, and TTX-siMYC, alongside its cancer vaccine and oncolytic immunotherapy platforms.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead therapeutic candidate, TTX-MC138, into a Phase 2a clinical trial in patients with ctDNA-positive colorectal cancer.
Expected impact: To demonstrate clinical efficacy in clearing ctDNA and achieving MRD negativity, validating the company's core RNA-targeted platform.
Expanding the oncology pipeline beyond RNA therapeutics by licensing three preclinical oncolytic adenovirus candidates (UIO-524, UIO-525, and UIO-526) from Unleash Immuno Oncolytics.
Expected impact: Establishes a presence in the multi-billion-dollar bladder cancer market, starting with muscle-invasive bladder cancer (MIBC).
Securing flexible financing of up to $20 million through a Standby Equity Purchase Agreement (SEPA) and prepaid advances via convertible notes with Yorkville Advisors.
Expected impact: Provides the necessary liquidity to support ongoing operations and clinical trials while avoiding heavy upfront dilutive commitments.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire Polynoma's clinical-stage melanoma vaccine candidate, Seviprotimut-L, and secure a $25 million strategic cash investment from Polynoma's parent company, CK Life Sciences.
Financial impact: The transaction was structured as an all-stock deal giving Polynoma's parent, CK Life Sciences, a 91% fully diluted stake in the combined company, accompanied by a concurrent $25 million cash and note investment. Additional milestone payments of up to $95 million may be payable.
Strategic Partnerships
Provides TransCode with exclusive worldwide rights to develop and commercialize three preclinical oncolytic adenovirus candidates, expanding its pipeline into immunotherapies.
Terms: All-stock transaction; Unleash received 1,136,364 shares of non-voting convertible preferred stock, representing 6.8% of TransCode's common stock on a fully diluted basis.
Accelerates clinical timelines and reduces costs for the Phase 2a trial of TTX-MC138 in colorectal cancer by leveraging Quantum Leap's established clinical trial network and platform sites.
Terms: Collaborative clinical trial framework; specific financial terms were not disclosed.
To explore combining TransCode's proprietary TTX delivery platform with Debiopharm's targeted drug delivery expertise to co-develop targeted nucleic acid therapeutics (specifically targeted mRNA delivery) for cancer.
Terms: Co-research collaboration; financial terms were not disclosed.